The NICE appraisal committee
In response to this, the company revised their submission to strengthen the evidence. The NICE committee
RCC starts in cells lining the small tubes in the kidney that help to make urine. In the advanced stage of the disease, the tumour spreads to other parts of the kidney, in some cases spreading to nearby lymph glands.
Cabozantinib is a small molecule that inhibits the growth of new blood vessels within a tumour, and so prevents it spreading.
Professor Carole Longson, Director of the Centre for Health Technology Evaluation at NICE said: “There
It is estimated that 1000 people with kidney cancer will be eligible for treatment with cabozantinib.
There were 9,023 people with kidney cancer in England in 2015. Between 2007 and 2015, this rose by 6%. Following this trend would mean more than 10,000 people could have kidney cancer this year.
UPDATE - The guidance became final on 9 August 2017. Local health authorities will have to make cabozantinib available to people who need it within three months of this date.